Suzhou Zelgen Biopharmaceuticals Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2009-03-18
- Employees
- 867
- Market Cap
- -
- Website
- https://www.zelgen.com
ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
Phase 1
Not yet recruiting
- Conditions
- Small Cell Lung CancerNeuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2025-06-26
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 350
- Registration Number
- NCT07038096
Study of ZG006 in Participants With Neuroendocrine Prostate Cancer
- First Posted Date
- 2025-06-17
- Last Posted Date
- 2025-06-17
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT07024277
- Locations
- 🇨🇳
Fudan university shanghai cancer center, Shanghai, Shanghai, China
Study of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: ZGGS18 for InjectionBiological: ZG005 for Injection
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06938880
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of ZG005 in Patients With Advanced Solid Tumors
Phase 2
Not yet recruiting
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: ZG005 for Injection
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 100
- Registration Number
- NCT06927687
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Phase 1
Not yet recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Biological: ZG005 for InjectionDrug: Gecacitinib Hydrochloride Tablets
- First Posted Date
- 2025-03-30
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 50
- Registration Number
- NCT06903377
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Phase 1
Not yet recruiting
- Conditions
- Lymphoma
- Interventions
- Biological: ZG005 for InjectionDrug: Gecacitinib Hydrochloride Tablets
- First Posted Date
- 2025-03-19
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06883526
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 30
- Registration Number
- NCT06592638
- Locations
- 🇺🇸
Zelgen Site 102, Plantation, Florida, United States
🇺🇸Zelgen Site 101, Canton, Ohio, United States
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
Phase 2
Recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT06558227
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 78
- Registration Number
- NCT06440057
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
Phase 1
Recruiting
- Conditions
- Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 93
- Registration Number
- NCT06372626
- Locations
- 🇨🇳
Chinese PLA General Hospital, Beijing, Beijing, China